NMTC vs. AKLI, FEMY, CODX, RVP, MDAI, NEPH, IINN, LNSR, DXR, and ICU
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Akili (AKLI), Femasys (FEMY), Co-Diagnostics (CODX), Retractable Technologies (RVP), Spectral AI (MDAI), Nephros (NEPH), Inspira Technologies Oxy B.H.N. (IINN), LENSAR (LNSR), Daxor (DXR), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.
Akili (NASDAQ:AKLI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
NeuroOne Medical Technologies received 57 more outperform votes than Akili when rated by MarketBeat users. Likewise, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 66.67% of users gave Akili an outperform vote.
NeuroOne Medical Technologies has higher revenue and earnings than Akili. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.
NeuroOne Medical Technologies has a net margin of -478.41% compared to NeuroOne Medical Technologies' net margin of -3,545.47%. NeuroOne Medical Technologies' return on equity of -76.34% beat Akili's return on equity.
53.1% of Akili shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 10.1% of Akili shares are owned by insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Akili has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Akili. MarketBeat recorded 4 mentions for NeuroOne Medical Technologies and 3 mentions for Akili. NeuroOne Medical Technologies' average media sentiment score of 1.28 beat Akili's score of 0.59 indicating that Akili is being referred to more favorably in the media.
Akili currently has a consensus price target of $4.00, indicating a potential upside of 1,281.22%. NeuroOne Medical Technologies has a consensus price target of $2.20, indicating a potential upside of 83.33%. Given NeuroOne Medical Technologies' higher probable upside, analysts clearly believe Akili is more favorable than NeuroOne Medical Technologies.
Summary
Akili and NeuroOne Medical Technologies tied by winning 8 of the 16 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NeuroOne Medical Technologies Competitors List
Related Companies and Tools